DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

Search

Exponent Inc

Slēgts

SektorsRūpniecība

69.41 -1.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

69.13

Max

70.24

Galvenie mērījumi

By Trading Economics

Ienākumi

1.5M

28M

Pārdošana

5.2M

147M

P/E

Sektora vidējais

35.084

40.202

Dividenžu ienesīgums

1.65

Peļņas marža

19.062

Darbinieki

976

EBITDA

6.8M

41M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+21.67% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.65%

2.12%

Nākamais dividenžu datums

2026. g. 20. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

174M

3.6B

Iepriekšējā atvēršanas cena

70.58

Iepriekšējā slēgšanas cena

69.41

Ziņu noskaņojums

By Acuity

61%

39%

378 / 454 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Exponent Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025. g. 31. dec. 13:01 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025. g. 31. dec. 11:10 UTC

Tirgus saruna

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025. g. 31. dec. 10:46 UTC

Tirgus saruna

Euro on Track For Strong Annual Performance -- Market Talk

2025. g. 31. dec. 10:25 UTC

Tirgus saruna

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025. g. 31. dec. 10:23 UTC

Tirgus saruna

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025. g. 31. dec. 09:33 UTC

Tirgus saruna

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Exponent Inc Prognoze

Cenas mērķis

By TipRanks

21.67% augšup

Prognoze 12 mēnešiem

Vidējais 85.5 USD  21.67%

Augstākais 90 USD

Zemākais 81 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Exponent Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

75.29 / 78.99Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

378 / 454 Rangs Rūpniecība

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Exponent Inc

Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering. The Environmental and Health segment offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. The company offers approximately 90 technical disciplines to solve pressing and complicated challenges facing stakeholders. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors of the economy. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
help-icon Live chat